Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 901–1,000 of 1,010
Hirayama, Y., Tam, T. W., Jian, K., Andersen, R. J., & Sadar, M. D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12770 · Cited by 53
Adrenally Directed Medical Therapies for Cushing Syndrome
Tritos, N. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa778 · Cited by 54
Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
Pardo, J. C. T., de Porras, V. R., Gil, J., Pous, A. F., Puig‐Domingo, M., & Jordà, M. (2022) · Nutrients · doi:10.3390/nu14040851 · Cited by 58
Drake, C. G., Sharma, P., & Gerritsen, W. R. (2013) · Oncogene · doi:10.1038/onc.2013.497 · Cited by 55
Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer
Lam, H., Ouyang, B., Chen, J., Ying, J., Wang, J., Wu, C., Li, J., Medvedovic, M., Vessella, R. L., & Ho, S. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0402 · Cited by 57
Bono, J. S. D., Piulats, J. M., Pandha, H., Petrylak, D. P., Saad, F., Aparicio, L. M. A., Sandhu, S. K., Fong, P. C. C., Gillessen, S., Hudes, G. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1869 · Cited by 51
Nilsson, S. F. (2016) · Current Oncology Reports · doi:10.1007/s11912-015-0495-4 · Cited by 53
Poon, D. M. C., Chan, K., Lee, S. H., Chan, T., Sze, H. C., Lee, E. K., Lam, D. C. M., & Chan, M. (2016) · BMC Urology · doi:10.1186/s12894-016-0132-z · Cited by 52
“exploratory analysis of the visceral disease subgroup in the COU-AA-301 study [6] has demonstrated that the presence of visceral disease is prognostic but not predictive of the response to AA [12].”
BackgroundConteduca, V., Crabb, S. J., Jones, R. J., Caffo, O., Elliott, T., Scarpi, E., Fabbri, P., Derosa, L., Massari, F., Numico, G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158952 · Cited by 52
“Over the last decade, an increasing number of novel drugs for castration-resistant prostate cancer (CRPC), including cabazitaxel [1], abiraterone acetate [2, 3], enzalutamide [4, 5], sipuleucelT [6], and radium-223 [7], have changed the scenario of prostate cancer (PC) management.”
BackgroundSelf-citationOptimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer
Lorente, D., Fizazi, K. S., Sweeney, C. J., & Bono, J. S. D. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.10.008 · Cited by 54
Self-citationLuo, Y., Azad, A. K., Karanika, S., Basourakos, S. P., Zuo, X., Wang, J., Yang, L., Yang, G., Korentzelos, D. K., Yin, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31237 · Cited by 51
“8 months.(3,4) This moderate increase in survival is likely due to the development of resistance that arises from aberrant regulation of AR target gene expression.”
BackgroundFunctional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Gao, X., Dai, C. S., Huang, S., Tang, J., Chen, G., Li, J., Zhu, Z., Zhu, X., Zhou, S., Gao, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2392 · Cited by 50
Dong, J., Wu, Z., Wang, D., Pascal, L. E., Nelson, J. B., Wipf, P., & Wang, Z. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0432 · Cited by 49
“B, C4-2 cells were transfected with expression vectors for GFP-tagged NTD, AR(1-293), and AR(294-556), along”
MethodMeyrick, D. P., Gallyamov, M., Sabarimurugan, S., Falzone, N., & Lenzo, N. P. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00801-w · Cited by 58
Androgens in prostate cancer: A tale that never ends
Hou, Z., Huang, S., & Li, Z. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.010 · Cited by 58
Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
Cieślikowski, W. A., Antczak, A., Nowicki, M. O., Zabel, M., & Budna, J. (2021) · Biomedicines · doi:10.3390/biomedicines9091179 · Cited by 56
“The cumulative analysis included the data of 6081 patients with mCRPC participating in COU-AA-301 [64], AFFIRM [66], ELM-PC-5 [67], ELM-PC-4 [68], and COMET-1 [69] studies.”
BackgroundMethodThe transcriptional programme of the androgen receptor ( AR ) in prostate cancer
Lamb, A. D. G., Massie, C. E., & Neal, D. E. (2013) · British Journal of Urology · doi:10.1111/bju.12415 · Cited by 58
Activin A Stimulates AKR1C3 Expression and Growth in Human Prostate Cancer
Hofland, J., van Weerden, W. M., Steenbergen, J., Dits, N. F. J., Jenster, G., & de Jong, F. H. (2012) · Endocrinology · doi:10.1210/en.2011-2065 · Cited by 48
Lǚ, K., Liu, C., Tao, T., Zhang, X., Zhang, L., Sun, C., Wang, Y., Chen, S., Xu, B., & Chen, M. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.04.037 · Cited by 48
“The major problem in PCa is the development and acquisition of castration-resistant prostate cancer (CRPC) phenotype, eventually leading to skeletal metastasis, at which no effective treatments are available [2].”
BackgroundMorken, J. D., Packer, A., Everett, R. A., Nagy, J. D., & Kuang, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3162 · Cited by 47
“The recent clinical efficacy of abiraterone (which inhibits intraprostatic androgen synthesis) and enzalutamide (a second-generation AR antagonist), has further confirmed that these cells are not androgen independent (5, 13, 14).”
BackgroundSonpavde, G., Bhor, M., Hennessy, D., Bhowmik, D., Shen, L., Nicacio, L., Rembert, D., Yap, M., & Schnadig, I. D. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.12.019 · Cited by 52
Active surveillance for prostate cancer: past, present and future
Singer, E. A., Kaushal, A., Türkbey, B., Couvillon, A., Pinto, P. A., & Parnes, H. L. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283527f99 · Cited by 54
Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel
Cheetham, P., & Petrylak, D. P. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e3182828d38 · Cited by 48
“Abiraterone acetate is a 17,20-lyase inhibitor, which totally abrogates synthesis of testosterone in the castrate-resistant prostate cancer cell.(11) Approved by the Food and Drug Administration as a treatment option for patients treated with docetaxel, randomized trials have demonstrated an 8.”
BackgroundFankhauser, M., Tan, Y., Macintyre, G., Haviv, I., Hong, M. K. H., Nguyen, A., Pedersen, J. S., Costello, A. J., Hovens, C. M., & Corcoran, N. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3483 · Cited by 50
“This is supported by evidence of receptor upregulation and nuclear localisation both in experimental systems and clinical samples, as well as the increased expression of AR regulated transcripts (notably KLK3/PSA) with disease progression, and confirmed by the recent clinical success of second line hormonal agents tha…”
BackgroundAdaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics
Scher, H. I., Nasso, S. F., Rubin, E. H., & Simon, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1105 · Cited by 51
“approved by the FDA for this indication (22).”
BackgroundSelf-citationCurrent and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer
Frieling, J. S., Basanta, D., & Lynch, C. C. (2015) · Cancer Control · doi:10.1177/107327481502200114 · Cited by 55
Ramalingam, S., Ramamurthy, V. P., & Njar, V. C. O. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.07.006 · Cited by 57
Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy
McKay, R. R., Jacobus, S. J., Fiorillo, M., Ledet, E. M., Cotogna, P. M., Steinberger, A. E., Jacene, H. A., Sartor, O. A., & Taplin, M. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.08.015 · Cited by 48
“Introduction The skeleton is the most frequent site of metastasis in metastatic castration-resistant prostate cancer (mCRPC).(1) Patients with bone metastases are vulnerable to skeletal morbidity leading to worsening”
BackgroundCost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
Pollard, M. E., Moskowitz, A. J., Diefenbach, M. A., & Hall, S. J. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.11.005 · Cited by 54
“In the phase III RCT, enzalutamide was administered for a mean treatment length of 8.3 months at US$7450 per month for a total treatment cost of US$61,835 [8].”
InfluentialRoyce, T. J., Chen, M., Wu, J., Loffredo, M. J., Renshaw, A. A., Kantoff, P. W., & D'Amico, A. V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5983 · Cited by 57
Crabb, S. J., Birtle, A. J., Martin, K., Downs, N., Ratcliffe, I. C., Maishman, T., Ellis, M., Griffiths, G. O., Thompson, S. D., Ksiazek, L., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0433-4 · Cited by 52
Self-citationRole of steroid receptor and coregulator mutations in hormone-dependent cancers
Groner, A. C., & Brown, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88885 · Cited by 51
“Additional treatments include adrenal androgen synthesis inhibitors, such as abiraterone (7, 8), and antagonists that prevent androgen/AR binding, such as enzalut-amide (9).”
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor
Licciardello, M. P., Ringler, A., Markt, P., Klepsch, F., Lardeau, C.-H., Sdelci, S., Schirghuber, E., Müller, A. C., Caldera, M., Wagner, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2382 · Cited by 54
Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Gordevičius, J., Kriščiūnas, A., Groot, D. E., Yip, S., Susic, M., Kwan, A., Kustra, R., Joshua, A. M., Chi, K. N., Petronis, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0101 · Cited by 52
“AA treatment improves survival and a number of surrogate endpoints, including decrease in PSA levels (3, 4).”
BackgroundSelf-citationLiquid Biopsy in Thyroid Cancer: New Insight.
Khatami, F., & Tavangar, S. M. (2018) · PubMed Central · Cited by 51
Briot, K., Paccou, J., Beuzeboc, P., Bonneterre, J. M., Bouvard, B., Confavreux, C. B., Cormier, C., Cortet, B., Hannoun‐Lévi, J., Hennequin, C., et al. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.09.017 · Cited by 50
Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer
Zou, L., Xiang, Q., Xue, X., Zhang, C., Li, C., Wang, C., Li, Q., Wang, R., Wu, S., Zhou, Y., et al. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0237-5 · Cited by 48
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
Conteduca, V., Mosca, A., Brighi, N., Giorgi, U. D., & Rescigno, P. (2021) · Cells · doi:10.3390/cells10010193 · Cited by 58
Cathomas, R. L., Rothermundt, C. A., Klingbiel, D., Bubendorf, L., Jaggi, R. B., Betticher, D. C., Brauchli, P., Cotting, D., Droege, C., Winterhalder, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2219 · Cited by 51
Kaboteh, R., Gjertsson, P., Leek, H., Lomsky, M., Ohlsson, M., Sjöstrand, K., & Edenbrandt, L. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-64 · Cited by 53
“Recently, however, new agents such as sipuleucel-T [3], cabazitaxel [4], denosumab [5], abiraterone [6], and MDV3100 [7] have”
BackgroundKanesvaran, R., Castro, E., Wong, A. S. C., Fizazi, K. S., Chua, M. L. K., Zhu, Y., Malhotra, H., Miura, Y., Lee, J. L., Chong, F. L. T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100518 · Cited by 51
Self-citationRoy, S., Sayyid, R. K., Fred Saad, C., Sun, Y., Lajkosz, K., Ong, M., Klaassen, Z. W. A., Malone, S. C., Spratt, D. E., Wallis, C. J. D., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.06.003 · Cited by 50
Puhr, M., Hoefer, J., Eigentler, A., Dietrich, D., van Leenders, G., Uhl, B., Hoogland, M., Handle, F., Schlick, B., Neuwirt, H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.292 · Cited by 48
Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.
Nightingale, G., & Ryu, J. H. (2012) · Europe PMC (PubMed Central) · Cited by 64
Glucocorticoids and prostate cancer treatment: friend or foe?
Montgomery, B., Cheng, H. H., Drechsler, J., & Mostaghel, E. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.125392 · Cited by 47
Kluth, L. A., Shariat, S. F., Kratzik, C., Tagawa, S. T., Sonpavde, G., Rieken, M., Scherr, D. S., & Pummer, K. (2013) · World Journal of Urology · doi:10.1007/s00345-013-1157-5 · Cited by 50
Bluemn, E. G., Spencer, E. S., Mecham, B., Gordon, R. R., Coleman, I., Lewinshtein, D., Mostaghel, E., Zhang, X., Annis, J., Grandori, C., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0710 · Cited by 47
“The development and clinical use of increasingly potent therapeutics targeting the AR and androgenic steroid production in prostate cancer (4, 5) is likely to select against those tumor cells relying on AR-mediated pathways for survival.”
BackgroundSpade, D. J., Hall, S. J., Saffarini, C. M., Huse, S. M., McDonnell, E. V., & Boekelheide, K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft266 · Cited by 50
“cancer (de Bono et al., 2011). We hypothesized that abiraterone acetate, but not DBP, would inhibit testosterone biosynthesis in human fetal testis xenografts. The model previously published by Heger et al. (2012) was modified to optimize measurements of antiandrogenic effects, using a human chorionic gonadotropin (hC…”
MethodHussain, M., Tangen, C. M., Higano, C. S., Vogelzang, N. J., & Thompson, I. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8065 · Cited by 52
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Yin, L., Hu, Q., & Hartmann, R. W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713958 · Cited by 49
“6 months, which is around 2 months longer than that of the placebo arm [44,45].”
BackgroundRegulation of vascular endothelial growth factor in prostate cancer
de Brot, S., Ntekim, A., Cardenas, R., James, V. H., Allegrucci, C., Heery, D. M., Bates, D. O., Ødum, N., Persson, J. L., & Mongan, N. P. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0123 · Cited by 55
“Although both abiraterone and enzalutamide have demonstrated survival benefits in the CRPC context, the duration of response to these agents remains disappointing (de Bono et al. 2011, Scher et al. 2012).”
BackgroundQi, W., Morales, C., Cooke, L. S., Johnson, B., Somer, B. G., & Mahadevan, D. (2015) · Oncotarget · doi:10.18632/oncotarget.5659 · Cited by 54
Ahaghotu, C. A., Tyler, R. C., & Sartor, O. A. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.12.003 · Cited by 51
Androgen synthesis in prostate cancer: do all roads lead to Rome?
Stuchbery, R., McCoy, P. J., Hovens, C. M., & Corcoran, N. M. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.221 · Cited by 59
Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
Jones, D. L., Noble, M. E. M., Wedge, S. R., Robson, C. N., & Gaughan, L. (2017) · Scientific Reports · doi:10.1038/srep40957 · Cited by 55
Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities
Alyamani, M., Li, Z., Berk, M. P., Li, J., Tang, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.05.020 · Cited by 50
“…disease, prolong survival and are FDA-approved for treatment of CRPC. Abiraterone inhibits the enzyme 17α-hydroxylase/17,20-lyase (CYP17A1) (de Bono et al., 2011; Ryan et al., 2012) and thus targets residual androgen synthesis, which suppresses AR signaling, whereas enzalutamide directly…”
BackgroundDe novo metastatic castration sensitive prostate cancer: State of art and future perspectives
Mosillo, C., Iacovelli, R., Ciccarese, C., Fantinel, E., Bimbatti, D., Brunelli, M., Bisogno, I., Kinspergher, S., Buttigliero, C., Tucci, M., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.005 · Cited by 50
Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies
van der Toom, E. E., Axelrod, H. D., de la Rosette, J. J. M. C. H., de Reijke, T. M., Pienta, K. J., & Valkenburg, K. C. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0119-5 · Cited by 55
Androgen receptor in breast cancer: A wolf in sheep’s clothing? A lesson from prostate cancer.
Salvi, S., Bonafè, M., & Bravaccini, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.04.002 · Cited by 48
Pain, opioid therapy, and survival: a needed discussion
Novy, D. M., Nelson, D. V., Koyyalagunta, D., Cata, J. P., Gupta, P., & Gupta, K. (2019) · Pain · doi:10.1097/j.pain.0000000000001736 · Cited by 49
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Lu, C., Brown, L. C., Antonarakis, E. S., Armstrong, A. J., & Luo, J. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0217-3 · Cited by 51
“The nextgeneration AR antagonists bind to the AR ligand-binding domain (LBD) with higher affinity than first-generation antiandrogens [6, 8], while abiraterone inhibits CYP17A1, a rate-limiting enzyme in the synthesis of adrenal and intratumoral androgens [5, 7].”
BackgroundBhagirath, D., Liston, M., Patel, N., Akoto, T., Lui, B., Yang, T. L., To, D. M., Majid, S., Dahiya, R., Tabatabai, Z. L., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01493-8 · Cited by 51
Cattrini, C., Caffo, O., Giorgi, U. D., Mennitto, A., Gennari, A., Olmos, D., & Castro, E. (2022) · Cancers · doi:10.3390/cancers14071792 · Cited by 49
Tewari, A. K., Cheung, A. T. M., Crowdis, J. P., Conway, J. R., Camp, S. Y., Wankowicz, S. A. M., Livitz, D. G., Park, J., Lis, R. T., Bosma-Moody, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109665 · Cited by 49
Advances with androgen deprivation therapy for prostate cancer
Yu, E.-M., & Aragon‐Ching, J. B. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2033210 · Cited by 51
Ha, S., Luo, G., & Xiang, H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01487 · Cited by 49
Dahut, W. L., Madan, R. A., Karakunnel, J. J., Adelberg, D. E., Gulley, J. L., Turkbey, I. B., Chau, C. H., Spencer, S. D., Mulquin, M., Wright, J., et al. (2013) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11667.x · Cited by 50
Galsky, M. D., Small, A., Tsao, C., & Oh, W. K. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21141 · Cited by 56
Current clinical challenges in prostate cancer.
Silberstein, J. L., Pal, S. K., Lewis, B. E., & Sartor, O. A. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.03 · Cited by 66
“In the COU-AA-301 trial, a total of 1,195 patients with mCRPC and prior docetaxel therapy were randomized in a 2:1 fashion to receive abiraterone or placebo (both with prednisone) (54).”
BackgroundMethodResultKumagai, J., Hofland, J., Erkens-Schulze, S., Dits, N. F. J., Steenbergen, J., Jenster, G., Homma, Y., de Jong, F. H., & van Weerden, W. M. (2013) · The Prostate · doi:10.1002/pros.22655 · Cited by 46
Adeniji, A. O., Uddin, M. J., Zang, T., Tamae, D., Wangtrakuldee, P., Marnett, L. J., & Penning, T. M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00160 · Cited by 47
Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer
Roubaud, G., Liaw, B. C.-H., Oh, W. K., & Mulholland, D. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.181 · Cited by 50
Alva, A. S., Nordquist, L. T., Daignault, S. D., George, S., Ramos, J., Albany, C., Isharwal, S., McDonald, M. J., Campbell, G. D., Danchaivijitr, P., et al. (2016) · The Prostate · doi:10.1002/pros.23286 · Cited by 47
“These novel agents include cytotoxic chemotherapy (docetaxel [3,4], cabazitaxel [5]), androgen signaling inhibitors (abiraterone [6,7], enzalutamide [8,9]), immunotherapy (sipuleucel-T [10]), and uniquely, a bone targeted agent, radium-223 [11].”
BackgroundCirculating steroid hormone variations throughout different stages of prostate cancer
Snaterse, G., Visser, J. A., Arlt, W., & Hofland, J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0155 · Cited by 50
Kim, E., Kim, J.-Y., Smith, M. A., Haura, E. B., & Anderson, A. R. A. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2002930 · Cited by 46
Saad, F., Sternberg, C. N., Mulders, P., Niepel, D., & TOMBAL, B. F. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.014 · Cited by 49
“In early clinical studies this led to hypokalaemia, fluid retention and hypertension; these events were largely abrogated by coadministration of low-dose glucocorticoids, such as prednisone or prednisolone [5,48,49].”
BackgroundSelf-citationAngelis, A., Linch, M. D., Montibeller, G., Molina-López, T., Zawada, A., Orzel, K., Arickx, F., Espín, J., & Kanavos, P. G. (2019) · Social Science & Medicine · doi:10.1016/j.socscimed.2019.112595 · Cited by 58
Medicinal Use of Testosterone and Related Steroids Revisited
Tauchen, J., Jurášek, M., Huml, L., & Rimpelová, S. (2021) · Molecules · doi:10.3390/molecules26041032 · Cited by 62
“Abiraterone use can cause tiredness, nausea, headache, hypertension, oedema, hypopotassemia, increased blood sugar, hot flashes, gastrointestinal discomfort, liver damage, and adrenocortical insufficiency [112].”
BackgroundBahl, A. K., Masson, S., Birtle, A. J., Chowdhury, S., & Bono, J. S. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.008 · Cited by 49
“AA was evaluated in COU-AA-301, a randomized, double-blind, Phase III trial in 1195 patients with mCRPC who had previously received docetaxel and had progressive disease (Table 1) [19].”
BackgroundMethodResultInfluentialRomero-Laorden, N., Lozano, R., Jayaram, A., López‐Campos, F., Sáez, M. I., Montesa, Á., Gutiérrez-Pecharromán, A., Villatoro, R., Herrera‐Imbroda, B., Correa, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0123-9 · Cited by 47
Li, K., Pang, J., Cheng, H., Liu, W., Di, J., Xiao, H.-J., Luo, Y., Zhang, H., Huang, W., Chen, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3192 · Cited by 53
“Recently sipuleucel-T [4], cabazitaxel [5], abiraterone (Zytiga) [6], and MDV3100 [7] have shown more prolonged overall survival benefit and have been approved by the FDA for treatment of the disease.”
BackgroundNomogram for overall survival of Japanese patients with bone-metastatic prostate cancer
Miyoshi, Y., Noguchi, K., Yanagisawa, M., Taguri, M., Morita, S., Ikeda, I., Fujinami, K., Miura, T., Kobayashi, K., & Uemura, H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1330-x · Cited by 48
Azad, A., Eigl, B. J., Leibowitz‐Amit, R., Lester, R. E., Kollmannsberger, C., Murray, N., Clayton, R., Heng, D. Y. C., Joshua, A. M., & Chi, K. N. (2014) · European Urology · doi:10.1016/j.eururo.2014.01.030 · Cited by 45
Self-citationFujimoto, N., Kubo, T., Inatomi, H., Bui, H. T. T., Shiota, M., Sho, T., & Matsumoto, T. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.23 · Cited by 48
Beardsley, E. K., Hotte, S. J., North, S. A., Ellard, S. L., Winquist, E., Kollmannsberger, C., Mukherjee, S. D., & Chi, K. N. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9722-5 · Cited by 48
“recently been approved by the US Food and Drug Administration for use in patients with CRPC [7].”
BackgroundSelf-citationCastration-resistant Prostate Cancer: Where We Stand in 2013 and What Urologists Should Know
Heidenreich, A., Pfister, D. J. K. P., Merseburger, A. S., & Bartsch, G. C. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.021 · Cited by 51
“The COU-AA-302 (Cougar 302) trial randomized 1088 men with mCRPC to receive abiraterone acetate with prednisone (AA/P) or placebo [2] with the primary end points of overall and radiographic progression-free survival (rPFS) by central review.”
MethodExploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer
Martin, S. K., & Kyprianou, N. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.03.001 · Cited by 54
Li, H., Wang, Z., Tang, K., Zhou, H., Liu, H., Yan, L., Guan, W., Chen, K., Xu, H., & Ye, Z. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.01.004 · Cited by 51
Obinata, D., Takayama, K., Takahashi, S., & Inoue, S. (2017) · Cancers · doi:10.3390/cancers9030022 · Cited by 53
Obara, W., Sato, F., Takeda, K., Kato, R., Kato, Y., Kanehira, M., Takata, R., Mimata, H., Sugai, T., Nakamura, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13278 · Cited by 49
Uemura, K., Kawahara, T., Yamashita, D., Jikuya, R., Abe, K., Tatenuma, T., Yokomizo, Y., Izumi, K., Teranishi, J., Makiyama, K., et al. (2017) · BioMed Research International · doi:10.1155/2017/7538647 · Cited by 46
“Several treatments, including enzalutamide (ENZ) [4, 5], abiraterone acetate (AA) [6, 7], docetaxel (DOC) [8, 9], cabazitaxel (CBZ) [10], radium-223 [11], and sipuleucel-T [11], have been shown to prolong overall survival (OS) in patients with metastatic CRPC (mCRPC).”
BackgroundFernández‐Cancio, M., Camats, N., Flück, C. E., Zalewski, A., Dick, B., Frey, B. M., Monné, R., Torán, N., Audí, L., & Pandey, A. V. (2018) · Pharmaceuticals · doi:10.3390/ph11020037 · Cited by 49
Apalutamide for the treatment of prostate cancer
Rathkopf, D. E., & Scher, H. I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1503954 · Cited by 48
Self-citationSuzuki, H., Shin, T., Fukasawa, S., Hashine, K., Kitani, S., Ohtake, N., Shibayama, K., Tran, N., Mundle, S. D., Fizazi, K. S., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa030 · Cited by 44
“Consistent with the previous studies conducted in patients with mCRPC in the global population (4, 9, 19, 20) and in the Japanese population (11–13), hypertension was commonly observed in this study.”
ResultSelf-citationTheranostics for Advanced Prostate Cancer: Current Indications and Future Developments
Farolfi, A., Fendler, W. P., Iravani, A., Haberkorn, U., Hicks, R. J., Herrmann, K., Walz, J. C., & Fanti, S. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.01.001 · Cited by 47
Slovin, S. F., Hussain, S. A., Fred Saad, C., García, J., Picus, J., Ferraldeschi, R., Crespo, M., Flohr, P., Riisnaes, R., Lin, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3212 · Cited by 45
Mori, K., Miura, N., Mostafaei, H., Quhal, F., Motlagh, R. S., Pradère, B., Kimura, S., Kimura, T., Egawa, S., Briganti, A., et al. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0222-6 · Cited by 46
Rosar, F., Wenner, F. N., Khreish, F., Dewes, S., Wagenpfeil, G., Hoffmann, M. A., Schreckenberger, M., Bartholomä, M. D., & Ezziddin, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05594-8 · Cited by 47
Disparities in germline testing among racial minorities with prostate cancer
Weise, N., Shaya, J. A., Javier-DesLoges, J. F., Cheng, H. H., Madlensky, L., & McKay, R. R. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00469-3 · Cited by 50
“COU-AA-301—Abiraterone post-chemo [83] 1195 NR NR NR NR NR NR NR”
BackgroundMehta, A. R., & Armstrong, A. J. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287215603558 · Cited by 41
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.